Pages that link to "Q41725318"
Jump to navigation
Jump to search
The following pages link to Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection (Q41725318):
Displaying 50 items.
- Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities (Q24550608) (← links)
- Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy (Q25257691) (← links)
- Immune Activation, Cd4+ T Cell Counts, and Viremia Exhibit Oscillatory Patterns over Time in Patients with Highly Resistant HIV Infection (Q28478654) (← links)
- The Use of Nonhuman Primate Models of HIV Infection for the Evaluation of Antiviral Strategies (Q30406868) (← links)
- Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times (Q30655744) (← links)
- The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance (Q33212237) (← links)
- Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America (Q33853922) (← links)
- Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations (Q33912028) (← links)
- Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy (Q33924628) (← links)
- The dynamics of CD4+ T-cell depletion in HIV disease (Q33942992) (← links)
- Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america (Q33981074) (← links)
- Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies (Q34228103) (← links)
- Opportunistic infections in HIV disease: down but not out. (Q34305079) (← links)
- Virologic and Immunologic Response to Highly Active Antiretroviral Therapy (Q34537487) (← links)
- Human retroviruses after 20 years: a perspective from the past and prospects for their future control (Q34792498) (← links)
- HIV disease and advanced age: an increasing therapeutic challenge (Q34967154) (← links)
- In Vivo Validation of a Bioinformatics Based Tool to Identify Reduced Replication Capacity in HIV-1 (Q34991044) (← links)
- Fitness of drug resistant HIV-1: methodology and clinical implications (Q35046895) (← links)
- A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan Africa (Q35126864) (← links)
- High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. (Q35156558) (← links)
- When to Start Antiretroviral Therapy and What to Start With-- A European Perspective (Q35179334) (← links)
- Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness (Q35217495) (← links)
- Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy (Q35264750) (← links)
- Treatment of antiretroviral-drug-resistant HIV-1 infection (Q35610798) (← links)
- Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure (Q35698801) (← links)
- Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy (Q35841783) (← links)
- Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression (Q35857259) (← links)
- Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy (Q36011358) (← links)
- Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity (Q36132255) (← links)
- Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial (Q36179320) (← links)
- CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States (Q36180809) (← links)
- The role of viral fitness in HIV pathogenesis (Q36223846) (← links)
- Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy (Q36428713) (← links)
- Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults (Q36548076) (← links)
- The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa (Q36555263) (← links)
- Virus-like particles: designing an effective AIDS vaccine (Q36602273) (← links)
- Systemic Cytokine Levels Do Not Predict CD4(+) T-Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection (Q36661588) (← links)
- The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting (Q36763062) (← links)
- Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa (Q36793768) (← links)
- Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings (Q36877987) (← links)
- Evaluation of WHO immunologic criteria for treatment failure: implications for detection of virologic failure, evolution of drug resistance and choice of second-line therapy in India (Q36902291) (← links)
- History-adjusted marginal structural models for estimating time-varying effect modification (Q36924003) (← links)
- Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring (Q36933327) (← links)
- CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals (Q37072697) (← links)
- HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. (Q37090735) (← links)
- Repositioning HIV protease inhibitors as cancer therapeutics (Q37192579) (← links)
- Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection (Q37309633) (← links)
- Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. (Q37371248) (← links)
- Nine-year follow-up of HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy. (Q37441637) (← links)
- Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen (Q37504245) (← links)